“Lindus Therapeutics is a next-generation drug development company. We advance portfolios of in-licensed assets, pairing our own asset identification and selection capability with an integrated clinical trial execution platform. Domain experts work hand in glove with proprietary AI systems, so we…”
Officer details are public data from the Companies House register.
People and entities with significant control, from the Companies House PSC register
Figures from 2024 accounts. Newer accounts, made up to 31 March 2025, are filed but not read yet. See them on Companies House
| 2024 | 2023 | 2022 | |
|---|---|---|---|
| Fixed Assets | £66,664 | £24,928 | £13,455 |
| Current Assets | £13,396,073 | £2,838,965 | £2,808,146 |
| Debtors | £1,927,510 | £560,563 | £127,507 |
| Cash | £11,468,563 | £2,278,402 | £2,680,639 |
| Creditors (> 1 year) | £54 | ||
| Net Current Assets | £12,746,774 | £2,735,025 | £2,771,339 |
| Net Assets | £12,803,504 | £2,755,215 | £2,784,740 |
Recent filings only. See the full history on Companies House
| Date | Description | Made Up To | Pages | |
|---|---|---|---|---|
| 29 October 2026 | Statement of capital following an allotment of shares | |||
| 29 October 2026 | Statement of capital following an allotment of shares | |||
| 28 October 2026 | Statement of capital following an allotment of shares | |||
| 3 September 2026 | Termination of appointment of a director |
Need accounts figures, ownership or websites for thousands of companies? Bulk data & API →